A Study of an Integrated Approach to Treating Recurrent Lung Adenocarcinomas Resistant to Tyrosine Kinase Inhibitors


About this study

The purpose of this study is identify molecular changes in recurring lung cancer tumors, and to determine the most significant genes, pathways and clinical characteristics in these lung adenocarcinomas which are resistant to tyrosine kinase inhibitor.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • 18 years or older
  • Lung adenocarcinoma tumors positive for any targetable genetic alterations
  • Have shown by CT/PET scan a partial or no response, progression or recurrence while on or after gene targeted therapy
  • Tumor is accessible for biopsy or surgery
  • Expected life is 6 months or longer


Exclusion Criteria

  • < 18 years
  • Lung cancer other than adenocarcinoma
  • Not able to communicate in English

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Jin Jen, M.D., Ph.D.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions